TRAX advances CD122 antibody for celiac and EoE; phase I-B soon
TRAX, newly formed from a spinout, is developing a dual-mechanism CD122 antibody for celiac disease and EoE. Phase I-B data are expected soon, with plans to expand into additional indications.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.